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Executive Summary 
Currently there are no studies examining the impact of medical cannabis 
programs on controlled substance prescribing. The intent of this study is to conduct a 
preliminary investigation into whether cannabis substitution for prescription drugs results 
in lower rates of controlled substance use. The hypothesis is that controlled substance use 
(in this project, defined by controlled substance supply) will decline in states after the 
introduction of medical cannabis programs. 
State and year–specific per capita retail distributions of the seven most commonly 
prescribed opioid drugs (fentanyl, hydrocodone, hydromorphone, meperidine, 
methadone, morphine, and oxycodone) were obtained from the Automation of Reports 
and Consolidated Orders System (ARCOS) of the US Drug Enforcement Administration 
(DEA).  All drugs were converted to morphine equivalents.  Dummy variables were used 
for the presence or absence of a Prescription Drug Monitoring Program (PDMP) and/or a 
Medical Marijuana Program (MMP).  A regression analysis for a fixed-effects model 
with one-way analysis was used to evaluate the impact of a state medical marijuana 
program on controlled substance distributions.   
Throughout the analyses neither the MMP nor PDMP effect was shown to have a 
statistically significant impact on the total amount of grams of morphine equivalents 
distributed.  Based upon these results, I conclude that the implementation of Medical 
Marijuana Programs does not cause a decline in prescription controlled substance 
utilization.  Due to the limit of the control variables included within the study there needs 
to be further research on the effects, if any, that Medical Marijuana Programs have on the 
use of prescription controlled substances. 
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Background 
 Marijuana has been a source of controversy within the United States both in its 
use as a recreational drug and in its use for medicinal purposes.  Despite being classified 
as an illicit drug, its rate of use has increased from 5.8 to 6.9 percent from 2007 to 2010.  
Marijuana holds the position as the most commonly used illicit drug with 17.4 million 
past month users [1].  These figures come from the National Survey on Drug Use and 
Health (NSDUH), which is sponsored by the Substance Abuse and Mental Health 
Services Administration (SAMHSA) through the U.S. Department of Health and Human 
Services.  NSDUH collects both state-level and national level data for the United States 
on the use of tobacco, alcohol, illicit drugs, and mental health services [1].  Marijuana is 
also the third most commonly used recreational drug behind alcohol and tobacco [2].  
Even though marijuana remains illegal as a recreational drug throughout the U.S., an 
increasing number of states have passed legislation to legalize its medicinal use.   
The most prevalent of these medicinal uses is for the treatment of pain, which has 
typically been treated with prescription medications, such as opioids.  This study seeks to 
determine if a substitution of medical marijuana for opioids results in a lower use of 
opioids. 
 
Gateway Theory 
 Whether the topic has been the legalization of recreational or medical marijuana, 
a centerpiece to the controversy has involved what has been termed the Gateway Theory. 
The Gateway Theory originated in 1975 when Dr. Denise Kandel conducted two 
longitudinal surveys that found high school students in New York used psychoactive 
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drugs following a systematic sequence.  Survey results showed that high school students 
were first initiating alcohol and cigarettes, followed by marijuana, and then onto “harder” 
drugs1 (cocaine, heroin, LSD) [4].  Since then, alcohol, tobacco, and marijuana have 
generally been categorized as ‘gateway’ drugs [5].  
 
Supporters  
Supporters of the Gateway Theory believe it represents a cause and effect 
relationship.  This means that if an individual utilizes marijuana, they are more likely to 
use harder drugs than those who do not use marijuana. The causative relationship implies 
that if marijuana legalization occurred, there would be an increase in the consumption of 
harder drugs. Hence, those against legalizing marijuana argue that doing so would result 
in an increased use of other drugs like cocaine and heroin [5]. 
 
Opponents 
 Those who oppose the Gateway Theory do not see it as an example of causality, 
but only as an example of correlation.  Some argue that this correlation is due to an 
unknown heterogeneity [5].  In this instance, an unknown heterogeneity represents an 
underlying trait that increases an individual’s susceptibility to tobacco use and their 
susceptibility to marijuana use.  Another observation by opponents is that the sequence of 
drug progression is more attributable to the likelihood of being exposed to that particular 
drug.  In other words, people are more likely to be exposed to alcohol, cigarettes, or 
cannabis than harder drugs.   !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!1!“Harder” drug: Any intensely addictive substance of abuse that may compel its user to commit crimes to !
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Despite extensive studies regarding the Gateway Theory, a definitive answer to 
the argument still eludes both sides.  This has not hindered the growing U.S support for 
the legalization of marijuana; such support has reached a high of 50% in favor as noted 
by a recent Gallup poll [6].  In addition, 70% of Americans say they would be in favor of 
making marijuana a legal option for doctors to prescribe to their patients [6].  This 
majority support can be seen in the growing number of states that are passing legislation 
to make medical marijuana available to patients who qualify for treatment [7].  Questions 
from the Gallup polls regarding both illicit and medical marijuana can be found in 
Appendix A. 
 
Medical Marijuana 
Medical marijuana patients represent a population of marijuana users who are 
able to maintain a legally reliable supply of marijuana.  Currently, medical marijuana 
does not fall under a standardized prescription system and is only available through a 
physician’s referral.  Through the referral process, patients in most states become 
registered and are then issued medical marijuana cards.  Some states have also 
established either state-run or non-profit dispensaries that cater to their registrants.  
 From the process of a physician’s referral, patients are essentially allowed to self-
medicate according to the amount and frequency that the patient feels is necessary.  This 
is different from how other medications are generally prescribed.  In most cases patients 
have a defined amount and frequency of use for prescription medications.  Even in the 
instances where medications are prescribed “as needed,” the prescription would still 
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establish a minimum and maximum range of use.  At this time, there are 16 states that 
have implemented a medical marijuana program (see Figure A)[8]. 
 
 
Figure A. States with a Medical Marijuana Program as of 9/26/11 [8,9] 
 
 
 
Common Diagnoses 
The most common conditions for which physicians are recommending the use of 
medical marijuana are pain, muscle spasms, headaches, insomnia, and anxiety [10]; pain 
represents the largest category with diagnoses such as spinal stenosis, degenerative disc 
disease, and lumbar disc displacement [10].  Chronic pain conditions are commonly 
treated with prescription controlled substances namely the opioid class [11,12].  A 
controlled substance is any drug or therapeutic agent—commonly understood to include 
narcotics, with a potential for abuse or addiction, which is held under strict governmental 
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control, as delineated by the Comprehensive Drug Abuse Prevention & Control Act 
passed in 1970 [13].   
 
Substitution 
 A recent anonymous survey at a medical marijuana dispensary in Berkeley 
California found that medical marijuana patients (n=351) are consciously substituting 
marijuana in place of alcohol (47%), illicit drugs (26%), and prescription medications 
(66%) [14].  Substitution in the study was defined as a patient making a conscious 
decision to utilize a particular drug (marijuana) over another.  Results of the survey 
showed the patients’ reasons for substituting marijuana were to avoid adverse side effects 
(65%), to more effectively control symptoms (57%), to decrease withdrawal potential 
(34%), ability to obtain marijuana (17.8%), greater social acceptance (11.9%), or some 
other reason (12.2%) [14]. 
 Even with the vast research that has been devoted to marijuana’s controversial 
capacity to lead to harder drugs, there are currently no studies examining the impact of 
medical marijuana programs on prescription controlled substance use. The intent of this 
study is to conduct a preliminary investigation into whether marijuana substitution for 
prescription drugs results in lower rates of prescription controlled substance use.  If 
medical marijuana patients are substituting marijuana for prescription pain medications, it 
is possible that fewer opioids will be distributed in states with medical marijuana 
programs.  This act of substitution implies that marijuana, within a particular population, 
is actually a gateway to less use of prescription controlled substances.  Many prescription 
controlled substances, including the ones in this study, can be viewed as harder drugs.  
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Instead of leading to harder drugs, marijuana may in fact be diverting patients from 
harder drug use.  The hypothesis is that prescription controlled substance use (in this 
project, defined by prescription controlled substance supply) will decline in states after 
the introduction of Medical Marijuana Program (MMP). 
 
Methods 
 This study will investigate whether the presence of a Medical Marijuana Program 
in a state will result in a decrease in prescription opioid distribution.  A regression 
analysis for a fixed-effects model with one-way analysis was used to evaluate the impact 
of a state medical marijuana program on prescription controlled substance distributions.  
Statistical Analytic Software (SAS) 9.3 was used to perform the analysis of this study.   
State and year–specific per capita (1997-2006) retail distributions of prescription 
controlled substances were obtained from the Automation of Reports and Consolidated 
Orders System (ARCOS) of the US Drug Enforcement Administration (DEA).  ARCOS 
data is a mandatory quarterly reporting system that is submitted by drug manufacturers 
and distributors.  The report details all prescription controlled substance transactions for a 
select list of prescription controlled substances.  This allows the DEA to track selected 
prescription controlled substance inventories and transactions from the time of 
manufacture to the time of sale, distribution, or other disposition, culminating in the 
drug’s dispensing to the consumer [15].   All 50 states and the District of Columbia (D.C) 
were included in the data.   
 The prescription controlled substances for the analysis were restricted to include 
the seven more commonly prescribed opioid drugs: fentanyl, hydrocodone, 
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hydromorphone, meperidine, methadone, morphine and oxycodone [16].  An issue with 
this list of opioids is the varying degrees of the individual drug’s potency.  As a method 
of accounting for variations in potency each drug was weighted based upon its oral 
milligram ratio to morphine (Table 1) [17,18].  By weighting these drugs they are 
converted to what is termed as morphine equivalents.  To illustrate the weight system, 1 
milligram of morphine is equal to 0.1 milligram of meperidine.  The total grams of 
morphine equivalents per capita by state and year can be found in Appendix B. 
 
Table 1. Equianalgesic Dosing [17,18] 
Drug Weight 
Morphine 1 
Meperidine 0.1 
Oxycodone 1.46 
Hydrocodone 4 
Hydromorphone 4.57 
Methadone 10.24 
Fentanyl 74.17 
 
 
Prescription Drug Monitoring Programs (PDMP) represent programs designed to 
avert and discover acts of diversion and abuse of prescription controlled substances [19].  
This study includes PDMPs as a control variable because prior studies have shown the 
presence of these programs to have an effect on controlled substance prescribing [19].     
States were evaluated on an annual basis as to whether a PDMP or a MMP was 
present.  PDMP presence or absence was obtained from the Alliance of States with 
Prescription Monitoring Programs [20].  The presence or absence of a MMP was 
retrieved from the National Organization for the Reform of Medical Marijuana Laws [8].  
Dummy variables were implemented for each program with 0 representing the absence of 
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the program and 1 representing the presence of the program (see Appendix C).  Based 
upon the dummy variables, states were placed in one of four categories: states with 
neither a PDMP nor MMP; states with a PDMP; states with a MMP; or states with both a 
PDMP and a MMP.  Figure B shows each state and how they were categorized in the last 
year (2006) of the dataset.  Given the data sources used for this research, the project does 
not qualify as research involving human subjects; therefore, U.S. Department of Health 
and Human Services regulations at 45 CFR part 46 do not apply, and Institutional Review 
Board approval was not required [21]. 
 
 
Figure B. United States Categorization (2006) [8,9,20] 
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Results 
Both Group Effects and Categorical Time Effects: Toeplitz 
This regression model uses the Toeplitz covariance structure to look at the total 
amount of grams of morphine equivalents distributed per capita regressed with both the 
group effects (PDMP and MMP) and the time effects of each state.  The model looks at 
each effect separately, in addition, to the interactions between each program and time.  
An equation for this model is as follows,  
 
 !"##$%!"= !! + !!!!"!" + !!!"#!!" + !!!"#$! + !!!!"!"!"#$! + !!!"#!!"!"#$!+ !!! + !!!" 
 
 
where !"##$%!" is the total grams of morphine equivalents distributed per capita, !"#$! 
is treated as a categorical variable with 1997 as a reference point, !!! is the unobserved 
time-invariant effect for state k, and !!!" is the error term for state k.  !!"!" and !"#!!", respectively, are defined as 
 
 !!"!" = 10 !"!!"#"$!!!ℎ!"!!! !"!!"#$#%&!!"!!"#$!!!"ℎ!"#$%!  
 
 !"#!!" = 10 !"!!"#"$!!!ℎ!"!!!!"#!!!"#$#%&!!"!!"#$!!!"ℎ!"#$%!  
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The implementation of a PDMP decreases the total amount of morphine 
equivalents distributed per capita by 17,290 grams (Table 2), but this increase is not 
statistically significant (p-value=0.9456) (Table 3).  MMP is shown to cause an increase 
in total grams distributed (189,083 grams), but like PDMP implementation it is not 
statistically significant (p-value=0.6173).  Table 3 also illustrates that the time effect 
results in a statistically significant increase (p-value=<0.0001) in the total amount of 
grams distributed per capita with respect to the reference year.  From the reference year 
to 2006 the total amount of grams distributed per capita increased by 4,611,233 grams.  It 
is also important to note that even though the interactions between the time effect and the 
PDMP falls slightly short of being statistically significant with a p-value of 0.0683.   
 
Table 2. Group Effects (n=510): Toeplitz 
Effect Estimate Standard Error DF t Value Pr > |t| 
Intercept 1165113 647136 62.3 1.8 0.0766 
pdmp -17290 252238 57.7 -0.07 0.9456 
mmp 189083 376201 52.7 0.5 0.6173 
151 states (including D.C) with 10 years of observations 
  2Dependent variable=Estimate=Amount (in grams) of morphine equivalents distributed 
 
Table 3. Both Group and Categorical Time Effects (n=510): Toeplitz 
Effect Num DF Den DF F Value Pr > F 
pdmp 1 97 0 0.952 
mmp 1 116 0.13 0.719 
year 9 195 21.24 <.0001 
year*pdmp 9 130 1.83 0.0683 
year*mmp 9 137 1.51 0.151 
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Both Group Effects and Categorical Time Effects: Autoregressive 
 As in the previous model, this model looks at the group effects, time effects, and 
the interactions between them.  This model utilizes the same equation, but instead of a 
Toeplitz covariance structure, the model uses an Autoregressive covariance structure.  In 
this model, the implementation of a MMP decreases the total amount of morphine 
equivalents distributed per capita by 1,577,913 grams and the implementation of a PDMP 
decreases the total amount of morphine equivalents distributed per capita by 724,798 
grams, of which, neither are statistically significant (Table 4).  Once again there is a 
statistically significant increase in the total amount of morphine equivalents distributed 
per capita with respect to the time effects (p-value=<0.0001) and here the time effects 
interaction with a PDMP is also statistically significant (p-value=<.0001) (Table 5). 
 
 
Table 4. Group Effects (n=510): Autoregressive 
Effect Estimate Standard Error DF t Value Pr > |t| 
Intercept 1393978 709582 59.5 1.96 0.0541 
pdmp -724798 832561 494 -0.87 0.3844 
mmp -1577913 5268134 466 -0.3 0.7647 
151 states (including D.C) with 10 years of observations 
  2Dependent variable=Estimate=Amount (in grams) of morphine equivalents distributed 
  
 
Table 5. Both Group and Categorical Time Effects (n=510): Autoregressive 
Effect Num DF Den DF F Value Pr > F 
pdmp 1 486 0.39 0.5331 
mmp 1 470 0.52 0.472 
year 8 457 19.6 <.0001 
pdmp*year 7 456 11.26 <.0001 
mmp*year 7 456 0.77 0.6088 
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Conclusion 
 Neither the Toeplitz nor the Autoregressive covariance structure were able to 
show that the implementation of a MMP had a statistically significant impact on the total 
amount of grams of morphine equivalents distributed per capita.  Based upon these 
results, I conclude that the implementation of Medical Marijuana Programs does not 
cause a decline in prescription controlled substance utilization.  Due to the limited 
number of control variables included within the study there needs to be further research 
on the effects, if any, that Medical Marijuana Programs have on the use of controlled 
substances.   
 
Discussion 
Effects of MMP Implementation 
 Even though the study does not confirm the hypothesis it does illustrate the 
complicated environment that surrounds medical marijuana.  Despite the hesitation of 
some states to implement medical marijuana legislation legalizing its usage, it appears 
that when such legislation is in place it does not appear to increase the use of prescription 
controlled substances significantly within the framework of this study.  In other words, 
Medical Marijuana Programs may not decrease the use of prescription controlled 
substances, but they do not increase the rate of use either. 
 
Limitations of Analysis 
 General limitations of the study are that the results only identify associations at 
the state level and not the individual level.  Additionally, data are limited in capturing a 
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window before and after PDMP/MMP implementation, which limits the study’s ability to 
detect if these programs have a significant effect on the amount of prescription controlled 
substances distributed. 
The first limitation of the ARCOS data is that it presents an overrepresentation of 
the amounts of drug distributed.  It does this as a result of including not only the amount 
of drug distributed to the human population, but also the unknown amount distributed to 
the animal population (veterinary services).  The data also over-represents the amount 
actually consumed by patients, as it does not account for amounts of prescription 
controlled substances that expired, were stolen, and were damaged.  Another limitation is 
that the amount distributed in a given year are not necessarily dispensed or consumed by 
patients within the same year [22].  Lastly, drugs that are distributed to a state are not 
necessarily dispensed within that same state [17]. 
If the analysis was redone the first control variable to include would be the 
number of people registered with the state’s MMP.  This would better address the impact 
of Medical Marijuana Programs by tying the level of participation to the level of increase 
or decrease in the amount of prescription controlled substances distributed.  A problem 
with this particular control variable is the variability of how states define ‘registered’ 
patients and whether or not the state even requires any level of registry.   
The second control variable would be the percentage of medical marijuana 
patients using medical marijuana for the treatment of chronic pain.  As previously 
mentioned, one of the more common reasons patients were being referred for medical 
marijuana treatment was for chronic pain, but that study was limited to the state of 
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California.  This state consensus may not apply to all states to the same degree it did for 
California or may not even apply at all.   
The third control variable would be the level of monitoring that occurs with each 
state’s PDMP.  State PDMPs vary on which prescription controlled substances are 
monitored and the groups authorized to view the content included in the program.  In 
fact, not all states monitor all seven prescription controlled substances included within 
this study.  As a result, the effects of the presence of a PDMP may not be consistent 
between each state.   
 
Further Research 
Future research should evaluate the effects of medical marijuana programs on 
other common conditions that physicians are recommending the use of medical marijuana 
for, such as anxiety.  A class of drugs that theoretically might be affected by Medical 
Marijuana Programs and Prescription Drug Monitoring Programs would be the 
benzodiazepines.  Benzodiazepines are a class of drugs that have uses in the treatment of 
anxiety and insomnia, which are indications shared with medical marijuana.  Some state’s 
PDMPs also monitor this class of drugs making it an ideal future study. 
 An additional study could look into the effects of medical marijuana cost and how 
that, in the context of this study, would affect the distribution of prescription controlled 
substances.  To elaborate, medical marijuana is not covered by prescription insurance.  
The direct cost of medical marijuana to the patient with prescription drug coverage is 
much greater than other comparable drugs like those included in this study.  On the other 
hand, for patients without prescription drug coverage this may create a less expensive 
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alternative.  If the cost of medical marijuana decreased it would be possible that patients 
would utilize marijuana as a source of treatment substitution more frequently. 
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Appendix A. Gallup Questionnaire 
 
19. Do you think the use of marijuana should be made legal, or not? 
 
20. Would you favor or oppose making marijuana legally available for doctors  
to prescribe in order to reduce pain and suffering? 
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Appendix B. Total Grams of Morphine Equivalents Per Capita 
    STATE 1997 1998 1999 2000* 2001 2002 2003 2004 2005 2006 
ALASKA 171,356.82 252,883.56 302,302.59 216,691.35 507,244.04 605,805.97 676,745.25 752,927.87 744,251.95 809,890.48 
ALABAMA 1,784,597.91 2,010,871.69 2,532,549.01 2,333,703.62 3,571,373.65 4,140,227.88 5,292,871.85 5,616,350.52 6,366,001.16 7,287,815.93 
ARKANSAS 709,175.57 855,079.84 1,044,809.50 873,897.25 1,546,559.35 1,852,122.57 2,174,381.37 2,553,463.09 2,916,844.45 3,441,700.29 
ARIZONA 1,086,617.25 1,304,668.35 1,611,388.00 1,404,411.00 2,685,582.20 3,301,483.80 4,148,620.10 4,960,877.37 5,498,741.45 6,847,539.86 
CALIFORNIA 7,505,625.69 9,326,663.25 10,561,815.93 8,689,849.24 15,004,696.75 18,219,438.30 22,417,926.40 25,089,173.86 26,509,545.88 30,895,607.88 
COLORADO 825,337.23 975,219.76 1,190,875.06 934,403.68 1,868,967.99 2,167,634.23 2,590,272.96 2,910,041.00 3,298,446.99 3,699,878.96 
CONNECTICUT 683,058.35 854,133.26 1,026,682.34 891,034.98 1,566,478.05 1,954,943.47 2,310,255.80 2,674,231.65 2,745,799.40 3,081,685.84 
DISTRICT OF 
COLUMBIA 108,726.94 125,122.79 138,939.25 76,300.17 160,428.96 171,637.84 227,910.46 212,452.90 229,850.57 263,750.06 
DELAWARE 135,003.63 178,880.00 212,640.85 205,039.01 316,071.23 420,063.60 615,864.59 662,660.22 773,708.47 901,845.91 
FLORIDA 4,059,674.79 5,308,317.97 6,510,549.08 6,223,159.95 10,907,204.70 13,131,747.64 16,471,072.30 19,212,562.62 20,013,753.39 25,106,056.16 
GEORGIA 1,919,754.96 2,263,209.66 2,776,775.31 2,539,619.09 4,017,807.31 5,241,293.44 6,247,779.45 6,589,129.78 6,868,200.30 8,476,788.44 
HAWAII 195,211.02 228,904.43 237,916.50 213,852.08 518,741.98 617,128.92 777,442.33 912,518.19 938,928.62 1,089,613.41 
IOWA 389,089.30 455,370.62 544,138.57 446,152.26 837,498.89 1,073,995.41 1,349,130.57 1,542,176.02 1,644,984.50 1,850,025.07 
IDAHO 299,851.26 348,695.00 412,626.33 387,093.79 674,693.75 821,773.68 1,015,106.29 1,180,239.29 1,318,274.15 1,532,399.30 
ILLINOIS 1,739,272.59 2,054,223.33 2,431,995.47 2,032,201.04 3,503,804.13 4,182,789.23 5,065,729.56 5,782,168.32 6,122,288.17 7,689,188.77 
INDIANA 1,569,458.11 1,862,715.59 2,302,565.25 2,109,348.90 3,334,380.05 4,107,190.40 4,938,673.74 5,439,033.64 5,952,854.17 6,952,714.98 
KANSAS 543,787.32 582,717.81 746,536.74 595,994.51 1,107,667.92 1,395,898.43 1,811,719.19 2,060,313.06 2,443,015.27 2,986,155.18 
KENTUCKY 1,268,650.73 1,527,293.30 1,919,157.40 2,048,908.41 3,095,504.02 3,827,806.67 4,675,196.58 4,996,497.38 5,104,181.91 6,009,140.98 
LOUISIANA 1,229,167.88 1,529,491.45 1,846,377.55 1,855,218.52 2,869,954.48 3,688,781.85 4,820,158.34 5,815,197.60 6,839,363.35 7,495,348.65 
MASSACHUSETTS 1,229,288.19 1,627,149.32 1,987,076.17 1,405,964.68 2,780,251.52 3,412,328.30 3,909,416.65 4,323,328.60 4,392,984.72 4,954,895.37 
MARYLAND 1,006,137.23 1,284,741.58 1,618,932.35 1,225,325.54 2,141,404.27 2,674,344.61 3,398,761.04 3,568,651.14 4,202,601.63 4,512,013.41 
MAINE 233,095.58 308,125.42 440,686.49 354,769.34 760,234.53 951,282.73 1,105,988.51 1,358,174.85 1,458,687.90 1,696,584.65 
MICHIGAN 1,964,436.16 2,295,847.33 3,084,593.63 2,744,247.36 4,770,283.69 5,920,589.32 7,219,812.69 8,221,650.78 8,630,098.38 10,512,248.58 
MINNESOTA 517,071.18 665,967.01 810,267.82 581,193.03 1,325,285.23 1,589,542.39 1,974,356.07 2,226,973.66 2,401,185.67 2,721,158.02 
MISSOURI 1,112,396.84 1,435,996.84 1,735,671.44 1,672,046.71 3,068,746.00 3,737,325.05 4,501,171.36 5,222,666.64 5,750,291.18 5,857,964.18 
MISSISSIPPI 591,696.37 688,614.96 842,804.55 901,588.24 1,279,233.79 1,583,819.11 1,935,030.68 2,153,583.27 2,393,243.77 2,881,619.68 
MONTANA 184,239.42 228,653.20 295,700.37 243,997.21 487,660.60 625,290.86 765,855.96 898,144.43 995,372.48 1,129,194.30 
NEBRASKA 289,801.02 336,393.77 393,206.64 321,292.39 549,567.40 4,756,688.55 5,930,486.31 7,524,762.12 8,173,455.75 9,593,413.65 
NORTH CAROLINA 1,785,483.30 2,172,694.33 2,720,235.80 2,520,071.31 4,447,696.13 235,358.94 284,992.28 305,550.40 373,952.45 408,813.04 
NORTH DAKOTA 77,465.75 97,056.75 113,927.89 78,787.81 185,255.43 656,685.21 792,929.83 887,198.55 961,173.27 1,094,565.25 
NEW HAMPSHIRE 210,957.20 287,997.82 389,192.62 298,143.62 625,382.73 765,476.90 875,725.63 1,024,337.13 1,130,365.98 1,309,938.01 
NEW JERSEY 1,254,991.03 1,621,440.69 1,975,218.47 1,602,615.46 2,810,342.74 3,337,940.32 4,438,503.40 4,977,853.01 5,356,544.27 6,157,600.36 
NEW MEXICO 414,307.30 417,649.88 488,639.52 417,360.25 790,996.55 932,116.36 1,105,487.79 1,256,718.42 1,343,463.34 1,596,117.92 
NEVADA 694,957.32 883,383.68 1,066,698.90 958,562.80 1,847,333.25 2,704,758.14 3,373,492.18 3,866,731.88 3,851,288.18 4,937,700.92 
NEW YORK 2,680,693.78 3,559,149.23 4,052,606.45 3,114,611.59 6,076,422.22 7,718,292.66 9,581,764.17 10,617,722.71 11,436,842.22 12,710,684.86 
OHIO 2,257,226.32 2,642,139.41 3,312,631.10 3,260,031.24 5,220,937.42 6,376,992.41 7,973,899.77 9,461,087.95 10,210,618.97 11,865,501.01 
OKLAHOMA 929,897.17 1,140,444.29 1,320,608.94 1,383,414.37 2,183,270.70 2,622,408.51 3,293,656.67 3,840,214.57 4,241,682.33 5,058,575.02 
OREGON 905,859.98 1,110,622.86 1,445,331.51 1,151,019.25 2,369,748.03 2,912,018.63 3,667,501.27 4,251,050.61 4,600,260.16 5,702,587.60 
PENNSYLVANIA 2,634,974.43 3,208,104.71 4,091,358.52 3,348,615.69 5,716,841.71 6,827,481.75 8,775,226.79 9,371,765.90 10,252,597.40 11,728,977.90 
RHODE ISLAND 226,130.83 258,948.90 297,908.87 299,402.28 398,833.79 514,347.43 590,812.67 663,717.44 758,507.91 843,533.52 
SOUTH CAROLINA 813,810.17 965,982.21 1,277,992.83 1,416,381.57 1,899,855.81 2,559,468.59 3,137,224.42 3,484,361.65 3,601,456.37 4,469,222.14 
SOUTH DAKOTA 85,321.02 106,086.13 127,693.33 97,110.90 198,900.79 255,216.10 323,869.97 372,747.31 429,200.92 509,232.31 
TENNESSEE 1,598,952.80 1,898,003.46 2,436,273.41 2,311,555.50 3,801,219.46 5,022,802.25 6,684,023.87 8,066,705.88 8,801,442.57 11,183,047.86 
TEXAS 4,447,926.67 5,661,348.20 6,667,023.45 6,475,345.01 10,097,894.89 11,734,860.71 13,676,210.34 15,181,211.05 16,239,355.15 19,101,713.54 
UTAH 542,070.98 614,219.26 737,950.08 656,820.66 1,233,028.59 1,627,178.96 2,024,544.50 2,413,794.20 2,720,334.49 3,115,148.94 
VIRGINIA 1,359,268.89 1,616,104.23 2,112,663.86 1,796,551.61 3,201,829.87 3,862,439.47 4,647,269.61 4,975,726.93 5,242,107.53 5,977,252.92 
VERMONT 100,534.12 131,240.05 160,352.83 118,174.70 216,651.99 301,419.98 371,509.34 434,223.53 504,577.55 582,253.67 
WASHINGTON 1,515,326.04 1,840,293.87 2,253,271.27 1,729,475.50 3,579,143.52 4,310,247.75 5,452,795.74 6,417,228.99 6,988,235.48 8,400,984.37 
WISCONSIN 894,663.82 1,059,819.56 1,257,864.62 1,047,858.16 1,998,460.23 2,396,520.42 2,995,611.50 3,491,596.81 3,755,282.50 4,527,726.21 
WEST VIRGINIA 491,785.93 624,529.25 879,850.15 897,866.11 1,258,988.13 1,685,082.95 2,022,919.33 2,231,284.23 2,512,807.35 2,841,515.29 
WYOMING 93,618.78 106,637.19 124,505.84 104,200.77 199,872.07 257,993.41 329,671.30 370,309.87 403,987.80 470,120.86 
UNITED STATES 59,539,289.50 73,113,483.82 89,065,842.52 78,762,067.45 135,780,937.86 165,941,909.10 204,933,618.60 232,576,481.36 250,587,796.74 295,031,557.63 
           *In 2000 only two drugs were reported (oxycodone and hydrocodone) giving a falsely low grams of morphine equivalents for each state. 
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Appendix C. MMP (M) and PDMP (P) 
Dummy Variables                   1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 States M P M P M P M P M P M P M P M P M P M P 
ALASKA 0 0 0 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 
ALABAMA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 
ARKANSAS 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
ARIZONA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
CALIFORNIA 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
COLORADO 0 0 0 0 0 0 0 0 1 0 1 0 1 0 1 0 1 0 1 0 
CONNECTICUT 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
DISTRICT OF 
COLUMBIA 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
DELAWARE 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
FLORIDA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
GEORGIA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
HAWAII 0 1 0 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
IOWA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
IDAHO 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 
ILLINOIS 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 
INDIANA 0 0 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 
KANSAS 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
KENTUCKY 0 0 0 0 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 
LOUISIANA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
MASSACHUSETTS 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 
MARYLAND 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 1 0 1 0 
MAINE 0 0 0 0 1 0 1 0 1 0 1 0 1 0 1 1 1 1 1 1 
MICHIGAN 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 
MINNESOTA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
MISSOURI 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
MISSISSIPPI 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 
MONTANA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 1 0 
NORTH CAROLINA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
NORTH DAKOTA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
NEBRASKA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
NEW HAMPSHIRE 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
NEW JERSEY 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
NEW MEXICO 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 
NEVADA 0 1 0 1 0 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 
NEW YORK 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 
OHIO 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 
OKLAHOMA 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 
OREGON 0 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 
PENNSYLVANIA 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 
RHODE ISLAND 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 1 1 
SOUTH CAROLINA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
SOUTH DAKOTA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
TENNESSEE 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
TEXAS 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 
UTAH 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 
VIRGINIA 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 1 0 1 
VERMONT 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 1 0 
WASHINGTON 0 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 
WISCONSIN 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
WEST VIRGINIA 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 
